H3 Biomedicine Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
31
About the Report
About the Report
Summary
H3 Biomedicine Inc (H3 Biomedicine), a subsidiary of Eisai Co Ltd is a biopharmaceutical company that offers therapies. The company concentrates on discovery and early development of novel, targeted anti-cancer compounds. Its products include small-molecule drugs that are developed by utilizing synthetic chemistry approaches and advanced cell-based screening methods. H3 Biomedicine concentrates on scientific approaches and develops new platforms for multiple drug candidate programs. The company leverages the external and internal cumulative investment in cancer genomics to identify therapeutic targets and biomarkers. It operates in the areas of genomics, tumor biology, bioinformatics and innovative synthetic organic chemistry. The company operates through other biotechnology companies for research and development activities and advance cancer treatment options. H3 Biomedicine is headquartered in Cambridge, Massachusetts, the US.
H3 Biomedicine Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
H3 Biomedicine Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
H3 Biomedicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
H3 Biomedicine Inc, Medical Devices Deals, 2012 to YTD 2018 9
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Cancer Genetics Partners with H3 Biomedicine 11
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 12
H3 Biomedicine Extends Agreement with Selvita 13
H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 14
H3 Biomedicine Enters Into Agreement With Sage Bionetworks For Cancer-Genomics Research 15
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 16
Licensing Agreements 17
Compendia Bioscience Enters Into Licensing Agreement With H3 Biomedicine 17
H3 Biomedicine Inc-Key Competitors 18
H3 Biomedicine Inc-Key Employees 19
H3 Biomedicine Inc-Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Financial Announcements 21
Jan 08, 2018: H3 Biomedicine to Present 2018 Outlook at the 36th Annual J.P. Morgan Healthcare Conference 21
Corporate Communications 23
Jun 11, 2018: Eisai Names Lihua Yu As President & Chief Data Sciences Officer Of H3 Biomedicine 23
Feb 20, 2017: H3 Biomedicine Announces Appointment of Peter G. Smith, Ph. D., to Chief Scientific Officer 24
Product News 25
Apr 03, 2018: H3 Biomedicine Publishes Comprehensive Genomic Landscape Analysis in Cell Reports Revealing Breadth, Frequency and Potential Disease-Driving Significance of Somatic Mutations in RNA Splicing Factor Genes in Multiple Types of Cancer 25
03/09/2017: H3 Biomedicine to Present on H3B-6545 at 2017 American Association of Cancer Research Annual Meeting 27
Clinical Trials 28
Dec 06, 2017: H3 Biomedicine Presents Preclinical Data on Novel ERa Antagonist at San Antonio Breast Cancer Symposium 28
Sep 05, 2017: H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer 29
Jul 24, 2017: H3 Biomedicine and University of British Columbia Scientists Report Preclinical Data Describing Immune Evasion Mechanism in Muscle-Invasive Bladder Cancer 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31
List of Figure
List of Figures
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
H3 Biomedicine Inc, Medical Devices Deals, 2012 to YTD 2018 9
List of Table
List of Tables
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Key Facts 2
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
H3 Biomedicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
H3 Biomedicine Inc, Deals By Therapy Area, 2012 to YTD 2018 8
H3 Biomedicine Inc, Medical Devices Deals, 2012 to YTD 2018 9
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cancer Genetics Partners with H3 Biomedicine 11
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 12
H3 Biomedicine Extends Agreement with Selvita 13
H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 14
H3 Biomedicine Enters Into Agreement With Sage Bionetworks For Cancer-Genomics Research 15
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 16
Compendia Bioscience Enters Into Licensing Agreement With H3 Biomedicine 17
H3 Biomedicine Inc, Key Competitors 18
H3 Biomedicine Inc, Key Employees 19
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.